Free News Feed
Get our RSS Feed!
© Copyright 2026 StreetInsider.com
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
Citi analyst David Lebowitz reiterated a Buy rating and $389.00 price target on Madrigal Pharmaceuticals (NASDAQ: MDGL).
The analyst comments "We are closing our Catalyst Watch for Madrigal following the approval of Rezdiffra (resmetirom) for the treatment of noncirrhotic nonalcoholic steatohepatitis (NASH, also known as metabolic... More
H.C. Wainwright analyst Ed Acre raised the price target on Madrigal Pharmaceuticals (NASDAQ: MDGL) to $425.00 (from $405.00) while maintaining a Buy rating.
The analyst comments "Rezdiffra approved with a strong label that represents the "best case" for Madrigal's commercial opportunity. Yesterday, in a widely anticipated decision, Madrigal announced that the FDA has granted accelerated approval to Rezdiffra (resmetirom) as the first ever drug for MASH (formerly, NASH). We view the label as broad and highly supportive of the use of Rezdiffra as a foundational therapy in NASH patients with significant fibrosis. Specifically, the... More
Citi analyst David Lebowitz raised the price target on Madrigal Pharmaceuticals (NASDAQ: MDGL) to $389.00 (from $382.00) while maintaining a Buy rating.
The analyst comments "Madrigal announced that Rezdiffra (Resmetirom) was approved as the first therapy to treat non-cirrhotic non-alcoholic steatohepatitis (NASH, also known as metabolic... More